Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Triphendiol (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kazia Therapeutics; MEI Pharma; Novogen
- 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
- 26 May 2008 New trial record.
- 15 May 2008 Results will be reported at the 44th Annual Meeting of the American Society of Clinical Oncology.